Market Overview

AC Immune Out Positive On Crenezumab; What Does It Mean?

Share:
AC Immune Out Positive On Crenezumab; What Does It Mean?

Shares of AC Immune Ltd (NASDAQ: ACIU), a medical biotechnology company that focuses on the treatment of Alzheimer's disease (AD) and other neurodegenerative diseases, soared higher by more than 23 percent after the company's partner Genentech published an editorial.

AC Immune and Genentech have been teaming up for a decade. The editorial summarized the biology of AD and describes the importance of tau as a target in AD; it can be seen here.

AC Immune is far from the only company dedicated toward combating AD. Shares of Eli Lilly and Co (NYSE: LLY) tumbled in late November after the company announced its AD treatment candidate solanezumab didn't meet the primary endpoint in a late-stage clinical trial dubbed EXPEDITION3.

What Wall Street Thinks Of AC Immune

AC Immune began trading as a public company in late September. Here is a brief recap of what Wall Street analysts were saying once the quiet period ended:

  • Credit Suisse: Analysts at Credit Suisse initiated coverage of AC Immune with an Outperform rating and $18 price target. Among some of the bullish reasons to support the stock includes the fact that its AD treatments can continue even if Eli Lilly's own therapy is a "complete fail," since no AD assets are the same and designers differ.
  • Jefferies: Analysts at Jefferies initiated coverage of AC Immune with a Buy rating and $25 price target. The analysts noted that the company may have the "broadest" pipeline of drugs to treat AD within the biotech sector,which provides investors with a "multitude of catalysts" by 2018.

At last check, AC Immune shares were down 5.09 percent at $14.17.

Latest Ratings for ACIU

DateFirmActionFromTo
Dec 2019H.C. WainwrightReiteratesBuy
Feb 2019UBSDowngradesBuyNeutral
Nov 2018Leerink SwannInitiates Coverage OnOutperform

View More Analyst Ratings for ACIU
View the Latest Analyst Ratings

 

Related Articles (LLY + ACIU)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Health Care Initiation Analyst Ratings Movers Best of Benzinga

Latest Ratings

StockFirmActionPT
SFTDA DavidsonInitiates Coverage On13.0
PLLB. Riley FBRInitiates Coverage On
ORICCitigroupDowngrades
ROKUB of A SecuritiesMaintains500.0
BOXDA DavidsonDowngrades18.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com